A novel promising frontier for human health: The beneficial effects of nutraceuticals in cardiovascular diseases

International Journal of Molecular Sciences

Volumn 21, Issue 22, 2020, Pages 1-40

  Carrizzo, Albino ^a,b   Izzo, Carmine ^b   Forte, Maurizio ^a   Sommella, Eduardo ^c   Di Pietro, Paola ^b   Venturini, Eleonora ^a   Ciccarelli, Michele ^b   Galasso, Gennaro ^b   Rubattu, Speranza ^a,d   Campiglia, Petro ^b   Sciarretta, Sebastiano ^a,e   Frati, Giacomo ^a,e   Vecchione, Carmine ^a,b  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Berberine; Brassica; Cocoa; Curcumin; CVDs; Quercetin; Resveratrol; Spirulina platensis

Indexed keywords

BERBERINE; CURCUMIN; NUTRACEUTICAL; QUERCETIN; RESVERATROL; BIOLOGICAL PRODUCT;

ARTHROSPIRA PLATENSIS; ATHEROSCLEROSIS; BRASSICA; CACAO; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; REVIEW; CHEMISTRY; DIETARY SUPPLEMENT; HEALTH; SPIRULINA;

BERBERINE; BIOLOGICAL PRODUCTS; BRASSICA; CARDIOVASCULAR DISEASES; CURCUMIN; DIETARY SUPPLEMENTS; HEALTH; QUERCETIN; RESVERATROL; SPIRULINA;

EID: 85096238398     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms21228706     Document Type: Review

References (345)

1. Deaton, C.; Froelicher, E.S.; Wu, L.H.; Ho, C.; Shishani, K.; Jaarsma, T. The global burden of cardiovascular disease. Eur. J. Cardiovasc. Nurs. 2011, 10 (Suppl. 2), S5–S13. [CrossRef]
2. Castellano, J.M.; Narula, J.; Castillo, J.; Fuster, V. Promoting cardiovascular health worldwide: Strategies, challenges, and opportunities. Rev. Esp. Cardiol. (Engl. Ed.) 2014, 67, 724–730. [CrossRef] [PubMed]
3. Wong, N.D. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat. Rev. Cardiol. 2014, 11, 276–289. [CrossRef] [PubMed]
4. Tzoulaki, I.; Elliott, P.; Kontis, V.; Ezzati, M. Worldwide Exposures to Cardiovascular Risk Factors and Associated Health Effects: Current Knowledge and Data Gaps. Circulation 2016, 133, 2314–2333. [CrossRef] [PubMed]
5. Ravera, A.; Carubelli, V.; Sciatti, E.; Bonadei, I.; Gorga, E.; Cani, D.; Vizzardi, E.; Metra, M.; Lombardi, C. Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health. Nutrients 2016, 8, 363. [CrossRef]
6. Pletcher, M.J.; Moran, A.E. Cardiovascular Risk Assessment. Med. Clin. N. Am. 2017, 101, 673–688. [CrossRef]
7. Costantino, S.; Paneni, F.; Cosentino, F. Ageing, metabolism and cardiovascular disease. J. Physiol. 2016, 594, 2061–2073. [CrossRef]
8. Labarthe, D.R. Prevention of cardiovascular risk factors in the first place. Prev. Med. 1999, 29 Pt 2, S72–S78. [CrossRef]
9. Houston, M. The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease. Ther. Adv. Cardiovasc. Dis. 2018, 12, 85–108. [CrossRef]
10. Granato, D.; Barba, F.J.; Bursac Kovacevic, D.; Lorenzo, J.M.; Cruz, A.G.; Putnik, P. Functional Foods: Product Development, Technological Trends, Efficacy Testing, and Safety. Annu. Rev. Food. Sci. Technol. 2020, 11, 93–118. [CrossRef]
11. Roberfroid, M.B. A European consensus of scientific concepts of functional foods. Nutrition 2000, 16, 689–691. [CrossRef]
12. Sunkara, A.; Raizner, A. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment. Methodist Debakey Cardiovasc. J. 2019, 15, 179–184. [CrossRef] [PubMed]
13. Fortmann, S.P.; Burda, B.U.; Senger, C.A.; Lin, J.S.; Whitlock, E.P. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2013, 159, 824–834. [CrossRef] [PubMed]
14. Saneei, P.; Salehi-Abargouei, A.; Esmaillzadeh, A.; Azadbakht, L. Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: A systematic review and meta-analysis on randomized controlled trials. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 1253–1261. [CrossRef] [PubMed]
15. Ding, M.; Huang, T.; Bergholdt, H.K.; Nordestgaard, B.G.; Ellervik, C.; Qi, L.; Consortium, C. Dairy consumption, systolic blood pressure, and risk of hypertension: Mendelian randomization study. BMJ 2017, 356, j1000. [CrossRef] [PubMed]
16. Evans, C.E.; Greenwood, D.C.; Threapleton, D.E.; Gale, C.P.; Cleghorn, C.L.; Burley, V.J. Glycemic index, glycemic load, and blood pressure: A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2017, 105, 1176–1190. [CrossRef]
17. Sirtori, C.R.; Arnoldi, A.; Cicero, A.F. Nutraceuticals for blood pressure control. Ann. Med. 2015, 47, 447–456. [CrossRef] [PubMed]
18. Pagliaro, B.; Santolamazza, C.; Simonelli, F.; Rubattu, S. Phytochemical Compounds and Protection from Cardiovascular Diseases: A State of the Art. BioMed Res. Int. 2015, 2015, 918069. [CrossRef]
19. Oparil, S.; Acelajado, M.C.; Bakris, G.L.; Berlowitz, D.R.; Cifkova, R.; Dominiczak, A.F.; Grassi, G.; Jordan, J.; Poulter, N.R.; Rodgers, A.; et al. Hypertension. Nat. Rev. Dis. Primers 2018, 4, 18014. [CrossRef]
20. Seravalle, G.; Grassi, G. Obesity and hypertension. Pharmacol. Res. 2017, 122, 1–7. [CrossRef]
21. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018, 33, 3021–3104. [CrossRef]
22. Bakris, G.; Ali, W.; Parati, G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J. Am. Coll. Cardiol. 2019, 73, 3018–3026. [CrossRef]
23. Wang, C.; Chiang, C.; Yatsuya, H.; Hilawe, E.H.; Ikerdeu, E.; Honjo, K.; Mita, T.; Cui, R.; Hirakawa, Y.; Madraisau, S.; et al. Descriptive Epidemiology of Hypertension and Its Association With Obesity: Based on the WHO STEPwise Approach to Surveillance in Palau. Asia-Pac. J. Public Health 2017. [CrossRef]
24. Weber, T.; Lang, I.; Zweiker, R.; Horn, S.; Wenzel, R.R.; Watschinger, B.; Slany, J.; Eber, B.; Roithinger, F.X.; Metzler, B. Hypertension and coronary artery disease: Epidemiology, physiology, effects of treatment, and recommendations: A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension. Wien. Klin. Wochenschr. 2016, 128, 467–479. [CrossRef] [PubMed]
25. Shrestha, P.L.; Shrestha, P.A.; Vivo, R.P. Epidemiology of comorbidities in patients with hypertension. Curr. Opin. Cardiol. 2016, 31, 376–380. [CrossRef] [PubMed]
26. Georgianos, P.I.; Agarwal, R. Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat. Rev. Nephrol. 2016, 12, 636–647. [CrossRef] [PubMed]
27. Sarkar, T.; Singh, N.P. Epidemiology and Genetics of Hypertension. J. Assoc. Physicians India 2015, 63, 61–98.
28. Wong, N.D.; Franklin, S.S. Epidemiology of hypertension. J. Am. Soc. Hypertens. 2014, 8, 760–763. [CrossRef]
29. Qaseem, A.; Wilt, T.J.; Rich, R.; Humphrey, L.; Frost, J.; Forciea, M.A. Treatment of Hypertension in Adults over Age 60 to Higher Vs Lower Targets: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Fam. Med. 2017, 15, 185–186. [CrossRef]
30. Randel, A. AHA/ACC/ASH Release Guideline on the Treatment of Hypertension and CAD. Am. Fam. Physician 2015, 92, 1023–1030.
31. Ogihara, T. Antihypertensive treatment guideline for elderly hypertension. Nihon Rinsho 2001, 59, 919–926. [PubMed]
32. Persson, M.; Bohlin, J.; Eklund, P. Development and maintenance of guideline-based decision support for pharmacological treatment of hypertension. Comput. Methods Programs Biomed. 2000, 61, 209–219. [CrossRef]
33. Frohlich, E.D. Treatment guideline in the USA: Hypertension in the elderly. Br. J. Urol. 1998, 81 (Suppl. 1), 26–28. [CrossRef]
34. Delmas, D.; Jannin, B.; Latruffe, N. Resveratrol: Preventing properties against vascular alterations and ageing. Mol. Nutr. Food Res. 2005, 49, 377–395. [CrossRef] [PubMed]
35. Smoliga, J.M.; Baur, J.A.; Hausenblas, H.A. Resveratrol and health–a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55, 1129–1141. [CrossRef] [PubMed]
36. Lin, K.Y.; Ito, A.; Asagami, T.; Tsao, P.S.; Adimoolam, S.; Kimoto, M.; Tsuji, H.; Reaven, G.M.; Cooke, J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106, 987–992. [CrossRef] [PubMed]
37. Zordoky, B.N.; Robertson, I.M.; Dyck, J.R. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim. Biophys. Acta 2015, 1852, 1155–1177. [CrossRef]
38. Rivera, L.; Moron, R.; Zarzuelo, A.; Galisteo, M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77, 1053–1063. [CrossRef]
39. Dolinsky, V.W.; Chakrabarti, S.; Pereira, T.J.; Oka, T.; Levasseur, J.; Beker, D.; Zordoky, B.N.; Morton, J.S.; Nagendran, J.; Lopaschuk, G.D.; et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim. Biophys. Acta 2013, 1832, 1723–1733. [CrossRef]
40. Chan, V.; Fenning, A.; Iyer, A.; Hoey, A.; Brown, L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr. Pharm. Biotechnol. 2011, 12, 429–436. [CrossRef]
41. Rimbaud, S.; Ruiz, M.; Piquereau, J.; Mateo, P.; Fortin, D.; Veksler, V.; Garnier, A.; Ventura-Clapier, R. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS ONE 2011, 6, e26391. [CrossRef]
42. Hollenberg, N.K. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Curr. Hypertens. Rep. 2003, 5, 287–288. [PubMed]
43. Arunachalam, G.; Yao, H.; Sundar, I.K.; Caito, S.; Rahman, I. SIRT1 regulates oxidant-and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem. Biophys. Res. Commun. 2010, 393, 66–72. [CrossRef] [PubMed]
44. Cao, X.; Luo, T.; Luo, X.; Tang, Z. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens. Res. 2014, 37, 803–810. [CrossRef] [PubMed]
45. Agarwal, B.; Campen, M.J.; Channell, M.M.; Wherry, S.J.; Varamini, B.; Davis, J.G.; Baur, J.A.; Smoliga, J.M. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol. 2013, 166, 246–248. [CrossRef] [PubMed]
46. Annunziata, G.; Maisto, M.; Schisano, C.; Ciampaglia, R.; Narciso, V.; Tenore, G.C.; Novellino, E. Effects of Grape Pomace Polyphenolic Extract (Taurisolo((R))) in Reducing TMAO Serum Levels in Humans: Preliminary Results from a Randomized, Placebo-Controlled, Cross-Over Study. Nutrients 2019, 11, 139. [CrossRef]
47. Tome-Carneiro, J.; Larrosa, M.; Gonzalez-Sarrias, A.; Tomas-Barberan, F.A.; Garcia-Conesa, M.T.; Espin, J.C. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19, 6064–6093. [CrossRef]
48. Poulsen, M.M.; Vestergaard, P.F.; Clasen, B.F.; Radko, Y.; Christensen, L.P.; Stodkilde-Jorgensen, H.; Moller, N.; Jessen, N.; Pedersen, S.B.; Jorgensen, J.O. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62, 1186–1195. [CrossRef] [PubMed]
49. Sahebkar, A.; Serban, C.; Ursoniu, S.; Wong, N.D.; Muntner, P.; Graham, I.M.; Mikhailidis, D.P.; Rizzo, M.; Rysz, J.; Sperling, L.S.; et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors–Results from a systematic review and meta-analysis of randomized controlled trials. Int. J. Cardiol. 2015, 189, 47–55. [CrossRef]
50. Marques, B.; Trindade, M.; Aquino, J.C.F.; Cunha, A.R.; Gismondi, R.O.; Neves, M.F.; Oigman, W. Beneficial effects of acute trans-resveratrol supplementation in treated hypertensive patients with endothelial dysfunction. Clin. Exp. Hypertens. 2018, 40, 218–223. [CrossRef]
51. Liu, Y.; Ma, W.; Zhang, P.; He, S.; Huang, D. Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials. Clin. Nutr. 2015, 34, 27–34. [CrossRef] [PubMed]
52. Carrizzo, A.; Puca, A.; Damato, A.; Marino, M.; Franco, E.; Pompeo, F.; Traficante, A.; Civitillo, F.; Santini, L.; Trimarco, V.; et al. Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 2013, 62, 359–366. [CrossRef] [PubMed]
53. Theodotou, M.; Fokianos, K.; Mouzouridou, A.; Konstantinou, C.; Aristotelous, A.; Prodromou, D.; Chrysikou, A. The effect of resveratrol on hypertension: A clinical trial. Exp. Ther. Med. 2017, 13, 295–301. [CrossRef] [PubMed]
54. Movahed, A.; Ostovar, A.; Iranpour, D.; Thandapilly, S.J.; Raj, P.; Louis, X.L.; Smoliga, J.M.; Netticadan, T. The efficacy of resveratrol in controlling hypertension: Study protocol for a randomized, crossover, double-blinded, placebo-controlled trial. Trials 2016, 17, 296. [CrossRef] [PubMed]
55. Fraga, C.G. Cocoa, diabetes, and hypertension: Should we eat more chocolate? Am. J. Clin. Nutr. 2005, 81, 541–542. [CrossRef]
56. Cohen, D.L.; Townsend, R.R. Cocoa ingestion and hypertension-another cup please? J. Clin. Hypertens. (Greenwich) 2007, 9, 647–648. [CrossRef]
57. Rabadan-Chavez, G.M.; Reyes-Maldonado, E.; Quevedo-Corona, L.; Paniagua-Castro, N.; Escalona-Cardoso, G.; Jaramillo-Flores, M.E. The prothrombotic state associated with obesity-induced hypertension is reduced by cocoa and its main flavanols. Food Funct. 2016, 7, 4880–4888. [CrossRef]
58. Rostami, A.; Khalili, M.; Haghighat, N.; Eghtesadi, S.; Shidfar, F.; Heidari, I.; Ebrahimpour-Koujan, S.; Eghtesadi, M. High-cocoa polyphenol-rich chocolate improves blood pressure in patients with diabetes and hypertension. ARYA Atheroscler. 2015, 11, 21–29.
59. Fisher, N.D.; Hughes, M.; Gerhard-Herman, M.; Hollenberg, N.K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J. Hypertens. 2003, 21, 2281–2286. [CrossRef]
60. Nogueira Lde, P.; Knibel, M.P.; Torres, M.R.; Nogueira Neto, J.F.; Sanjuliani, A.F. Consumption of high-polyphenol dark chocolate improves endothelial function in individuals with stage 1 hypertension and excess body weight. Int. J. Hypertens. 2012, 2012, 147321. [CrossRef]
61. Engler, M.B.; Engler, M.M.; Chen, C.Y.; Malloy, M.J.; Browne, A.; Chiu, E.Y.; Kwak, H.K.; Milbury, P.; Paul, S.M.; Blumberg, J.; et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J. Am. Coll. Nutr. 2004, 23, 197–204. [CrossRef] [PubMed]
62. Schroeter, H.; Heiss, C.; Balzer, J.; Kleinbongard, P.; Keen, C.L.; Hollenberg, N.K.; Sies, H.; Kwik-Uribe, C.; Schmitz, H.H.; Kelm, M. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc. Natl. Acad. Sci. USA 2006, 103, 1024–1029. [CrossRef] [PubMed]
63. Heiss, C.; Dejam, A.; Kleinbongard, P.; Schewe, T.; Sies, H.; Kelm, M. Vascular effects of cocoa rich in flavan-3-ols. JAMA 2003, 290, 1030–1031. [CrossRef] [PubMed]
64. Grassi, D.; Necozione, S.; Lippi, C.; Croce, G.; Valeri, L.; Pasqualetti, P.; Desideri, G.; Blumberg, J.B.; Ferri, C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 2005, 46, 398–405. [CrossRef] [PubMed]
65. Balzer, J.; Rassaf, T.; Heiss, C.; Kleinbongard, P.; Lauer, T.; Merx, M.; Heussen, N.; Gross, H.B.; Keen, C.L.; Schroeter, H.; et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J. Am. Coll. Cardiol. 2008, 51, 2141–2149. [CrossRef]
66. Flammer, A.J.; Hermann, F.; Sudano, I.; Spieker, L.; Hermann, M.; Cooper, K.A.; Serafini, M.; Luscher, T.F.; Ruschitzka, F.; Noll, G.; et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007, 116, 2376–2382. [CrossRef]
67. Shiina, Y.; Funabashi, N.; Lee, K.; Murayama, T.; Nakamura, K.; Wakatsuki, Y.; Daimon, M.; Komuro, I. Acute effect of oral flavonoid-rich dark chocolate intake on coronary circulation, as compared with non-flavonoid white chocolate, by transthoracic Doppler echocardiography in healthy adults. Int. J. Cardiol. 2009, 131, 424–429. [CrossRef]
68. Heiss, C.; Kleinbongard, P.; Dejam, A.; Perre, S.; Schroeter, H.; Sies, H.; Kelm, M. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J. Am. Coll. Cardiol. 2005, 46, 1276–1283. [CrossRef] [PubMed]
69. Endale, M.; Park, S.C.; Kim, S.; Kim, S.H.; Yang, Y.; Cho, J.Y.; Rhee, M.H. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-kappaB-induced inflammatory mediators production in RAW 264.7 cells. Immunobiology 2013, 218, 1452–1467. [CrossRef] [PubMed]
70. Lee, K.M.; Hwang, M.K.; Lee, D.E.; Lee, K.W.; Lee, H.J. Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J. Agric. Food Chem. 2010, 58, 5815–5820. [CrossRef] [PubMed]
71. Kim, H.P.; Mani, I.; Iversen, L.; Ziboh, V.A. Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostaglandins Leukot. Essent. Fatty Acids 1998, 58, 17–24. [CrossRef]
72. Bureau, G.; Longpre, F.; Martinoli, M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 2008, 86, 403–410. [CrossRef] [PubMed]
73. Kempuraj, D.; Madhappan, B.; Christodoulou, S.; Boucher, W.; Cao, J.; Papadopoulou, N.; Cetrulo, C.L.; Theoharides, T.C. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br. J. Pharmacol. 2005, 145, 934–944. [CrossRef]
74. Nakajima, K.I.; Marunaka, Y. Intracellular chloride ion concentration in differentiating neuronal cell and its role in growing neurite. Biochem. Biophys. Res. Commun. 2016, 479, 338–342. [CrossRef] [PubMed]
75. Asano, J.; Niisato, N.; Nakajima, K.; Miyazaki, H.; Yasuda, M.; Iwasaki, Y.; Hama, T.; Dejima, K.; Hisa, Y.; Marunaka, Y. Quercetin stimulates Na+/K+/2Cl-cotransport via PTK-dependent mechanisms in human airway epithelium. Am. J. Respir. Cell Mol. Biol. 2009, 41, 688–695. [CrossRef]
76. Marunaka, Y.; Marunaka, R.; Sun, H.; Yamamoto, T.; Kanamura, N.; Inui, T.; Taruno, A. Actions of Quercetin, a Polyphenol, on Blood Pressure. Molecules 2017, 22, 209. [CrossRef]
77. Edwards, R.L.; Lyon, T.; Litwin, S.E.; Rabovsky, A.; Symons, J.D.; Jalili, T. Quercetin reduces blood pressure in hypertensive subjects. J. Nutr. 2007, 137, 2405–2411. [CrossRef]
78. Egert, S.; Bosy-Westphal, A.; Seiberl, J.; Kurbitz, C.; Settler, U.; Plachta-Danielzik, S.; Wagner, A.E.; Frank, J.; Schrezenmeir, J.; Rimbach, G.; et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: A double-blinded, placebo-controlled cross-over study. Br. J. Nutr. 2009, 102, 1065–1074. [CrossRef]
79. Zahedi, M.; Ghiasvand, R.; Feizi, A.; Asgari, G.; Darvish, L. Does Quercetin Improve Cardiovascular Risk factors and Inflammatory Biomarkers in Women with Type 2 Diabetes: A Double-blind Randomized Controlled Clinical Trial. Int. J. Prev. Med. 2013, 4, 777–785.
80. Conquer, J.A.; Maiani, G.; Azzini, E.; Raguzzini, A.; Holub, B.J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 1998, 128, 593–597. [CrossRef]
81. Serban, M.C.; Sahebkar, A.; Zanchetti, A.; Mikhailidis, D.P.; Howard, G.; Antal, D.; Andrica, F.; Ahmed, A.; Aronow, W.S.; Muntner, P.; et al. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Am. Heart Assoc. 2016, 5. [CrossRef] [PubMed]
82. Kondratiuk, V.E.; Synytsia, Y.P. Effect of quercetin on the echocardiographic parameters of left ventricular diastolic function in patients with gout and essential hypertension. Wiad. Lek. 2018, 71, 1554–1559. [PubMed]
83. Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: The Indian solid gold. Adv. Exp. Med. Biol. 2007, 595, 1–75. [CrossRef] [PubMed]
84. Satoskar, R.R.; Shah, S.J.; Shenoy, S.G. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986, 24, 651–654.
85. Li, H.L.; Liu, C.; de Couto, G.; Ouzounian, M.; Sun, M.; Wang, A.B.; Huang, Y.; He, C.W.; Shi, Y.; Chen, X.; et al. Curcumin prevents and reverses murine cardiac hypertrophy. J. Clin. Investig. 2008, 118, 879–893. [CrossRef]
86. Yao, Y.; Wang, W.; Li, M.; Ren, H.; Chen, C.; Wang, J.; Wang, W.E.; Yang, J.; Zeng, C. Curcumin Exerts its Anti-hypertensive Effect by Down-regulating the AT1 Receptor in Vascular Smooth Muscle Cells. Sci. Rep. 2016, 6, 25579. [CrossRef]
87. Tapia, E.; Soto, V.; Ortiz-Vega, K.M.; Zarco-Marquez, G.; Molina-Jijon, E.; Cristobal-Garcia, M.; Santamaria, J.; Garcia-Nino, W.R.; Correa, F.; Zazueta, C.; et al. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid. Med. Cell. Longev. 2012, 2012, 269039. [CrossRef]
88. Santos-Parker, J.R.; Strahler, T.R.; Bassett, C.J.; Bispham, N.Z.; Chonchol, M.B.; Seals, D.R. Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress. Aging (Albany NY) 2017, 9, 187–208. [CrossRef]
89. Kang, D.G.; Sohn, E.J.; Kwon, E.K.; Han, J.H.; Oh, H.; Lee, H.S. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. Vascul. Pharmacol. 2002, 39, 281–286. [CrossRef]
90. Olmez, E.; Ilhan, M. Evaluation of the alpha-adrenoceptor antagonistic action of berberine in isolated organs. Arzneimittelforschung 1992, 42, 1095–1097.
91. Chiou, W.F.; Yen, M.H.; Chen, C.F. Mechanism of vasodilatory effect of berberine in rat mesenteric artery. Eur. J. Pharmacol. 1991, 204, 35–40. [PubMed]
92. Ko, W.H.; Yao, X.Q.; Lau, C.W.; Law, W.I.; Chen, Z.Y.; Kwok, W.; Ho, K.; Huang, Y. Vasorelaxant and antiproliferative effects of berberine. Eur. J. Pharmacol. 2000, 399, 187–196. [CrossRef]
93. Lan, J.; Zhao, Y.; Dong, F.; Yan, Z.; Zheng, W.; Fan, J.; Sun, G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J. Ethnopharmacol. 2015, 161, 69–81. [CrossRef] [PubMed]
94. Liang, K.W.; Yin, S.C.; Ting, C.T.; Lin, S.J.; Hsueh, C.M.; Chen, C.Y.; Hsu, S.L. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. Eur. J. Pharmacol. 2008, 590, 343–354. [CrossRef] [PubMed]
95. Cheng, F.; Wang, Y.; Li, J.; Su, C.; Wu, F.; Xia, W.H.; Yang, Z.; Yu, B.B.; Qiu, Y.X.; Tao, J. Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int. J. Cardiol. 2013, 167, 936–942. [CrossRef]
96. Xu, M.G.; Wang, J.M.; Chen, L.; Wang, Y.; Yang, Z.; Tao, J. Berberine-induced upregulation of circulating endothelial progenitor cells is related to nitric oxide production in healthy subjects. Cardiology 2009, 112, 279–286. [CrossRef]
97. Affuso, F.; Ruvolo, A.; Micillo, F.; Sacca, L.; Fazio, S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr. Metab. Cardiovasc. Dis. 2010, 20, 656–661. [CrossRef]
98. Izzo, R.; de Simone, G.; Giudice, R.; Chinali, M.; Trimarco, V.; De Luca, N.; Trimarco, B. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J. Hypertens. 2010, 28, 1482–1487. [CrossRef]
99. Han, J.H.; Lee, H.J.; Kim, T.S.; Kang, M.H. The effect of glutathione S-transferase M1 and T1 polymorphisms on blood pressure, blood glucose, and lipid profiles following the supplementation of kale (Brassica oleracea acephala) juice in South Korean subclinical hypertensive patients. Nutr. Res. Pract. 2015, 9, 49–56. [CrossRef]
100. Wu, L.; Noyan Ashraf, M.H.; Facci, M.; Wang, R.; Paterson, P.G.; Ferrie, A.; Juurlink, B.H. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc. Natl. Acad. Sci. USA 2004, 101, 7094–7099. [CrossRef]
101. Rubattu, S.; Di Castro, S.; Cotugno, M.; Bianchi, F.; Mattioli, R.; Baima, S.; Stanzione, R.; Madonna, M.; Bozzao, C.; Marchitti, S.; et al. Protective effects of Brassica oleracea sprouts extract toward renal damage in high-salt-fed SHRSP: Role of AMPK/PPARalpha/UCP2 axis. J. Hypertens. 2015, 33, 1465–1479. [CrossRef] [PubMed]
102. Christiansen, B.; Bellostas Muguerza, N.; Petersen, A.M.; Kveiborg, B.; Madsen, C.R.; Thomas, H.; Ihlemann, N.; Sorensen, J.C.; Kober, L.; Sorensen, H.; et al. Ingestion of broccoli sprouts does not improve endothelial function in humans with hypertension. PLoS ONE 2010, 5, e12461. [CrossRef]
103. Kulshreshtha, A.; Zacharia, A.J.; Jarouliya, U.; Bhadauriya, P.; Prasad, G.B.; Bisen, P.S. Spirulina in health care management. Curr. Pharm. Biotechnol. 2008, 9, 400–405. [CrossRef] [PubMed]
104. Sommella, E.; Conte, G.M.; Salviati, E.; Pepe, G.; Bertamino, A.; Ostacolo, C.; Sansone, F.; Prete, F.D.; Aquino, R.P.; Campiglia, P. Fast Profiling of Natural Pigments in Different Spirulina (Arthrospira platensis) Dietary Supplements by DI-FT-ICR and Evaluation of their Antioxidant Potential by Pre-Column DPPH-UHPLC Assay. Molecules 2018, 23, 1152. [CrossRef]
105. Lu, J.; Ren, D.F.; Xue, Y.L.; Sawano, Y.; Miyakawa, T.; Tanokura, M. Isolation of an antihypertensive peptide from alcalase digest of Spirulina platensis. J. Agric. Food Chem. 2010, 58, 7166–7171. [CrossRef] [PubMed]
106. Pan, H.; She, X.; Wu, H.; Ma, J.; Ren, D.; Lu, J. Long-Term Regulation of the Local Renin-Angiotensin System in the Myocardium of Spontaneously Hypertensive Rats by Feeding Bioactive Peptides Derived from Spirulina platensis. J. Agric. Food Chem. 2015, 63, 7765–7774. [CrossRef] [PubMed]
107. Heo, S.Y.; Ko, S.C.; Kim, C.S.; Oh, G.W.; Ryu, B.; Qian, Z.J.; Kim, G.; Park, W.S.; Choi, I.W.; Phan, T.T.; et al. A heptameric peptide purified from Spirulina sp. gastrointestinal hydrolysate inhibits angiotensin I-converting enzyme-and angiotensin II-induced vascular dysfunction in human endothelial cells. Int. J. Mol. Med. 2017, 39, 1072–1082. [CrossRef] [PubMed]
108. Carrizzo, A.; Conte, G.M.; Sommella, E.; Damato, A.; Ambrosio, M.; Sala, M.; Scala, M.C.; Aquino, R.P.; De Lucia, M.; Madonna, M.; et al. Novel Potent Decameric Peptide of Spirulina platensis Reduces Blood Pressure Levels Through a PI3K/AKT/eNOS-Dependent Mechanism. Hypertension 2019, 73, 449–457. [CrossRef]
109. Miczke, A.; Szulinska, M.; Hansdorfer-Korzon, R.; Kregielska-Narozna, M.; Suliburska, J.; Walkowiak, J.; Bogdanski, P. Effects of spirulina consumption on body weight, blood pressure, and endothelial function in overweight hypertensive Caucasians: A double-blind, placebo-controlled, randomized trial. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 150–156.
110. Martinez-Samano, J.; Torres-Montes de Oca, A.; Luqueno-Bocardo, O.I.; Torres-Duran, P.V.; Juarez-Oropeza, M.A. Spirulina maxima Decreases Endothelial Damage and Oxidative Stress Indicators in Patients with Systemic Arterial Hypertension: Results from Exploratory Controlled Clinical Trial. Mar. Drugs 2018, 16, 496. [CrossRef]
111. Huang, H.; Liao, D.; Pu, R.; Cui, Y. Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure. Diabetes Metab. Syndr. Obes. 2018, 11, 729–742. [CrossRef] [PubMed]
112. Juarez-Oropeza, M.A.; Mascher, D.; Torres-Duran, P.V.; Farias, J.M.; Paredes-Carbajal, M.C. Effects of dietary Spirulina on vascular reactivity. J. Med. Food 2009, 12, 15–20. [CrossRef] [PubMed]
113. Torres-Duran, P.V.; Ferreira-Hermosillo, A.; Juarez-Oropeza, M.A. Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: A preliminary report. Lipids Health Dis. 2007, 6, 33. [CrossRef] [PubMed]
114. Insull, W., Jr. The pathology of atherosclerosis: Plaque development and plaque responses to medical treatment. Am. J. Med. 2009, 122 (Suppl. 1), S3–S14. [CrossRef] [PubMed]
115. Titov, V.N.; Shiriaeva Iu, K. Arteriolosclerosis and atherosclerosis. Pathology of the distal and proximal arterial bed. Pathogenesis of diabetic microangiopathy. Klin. Lab. Diagn. 2011, 4, 3–14.
116. Kolodgie, F.D.; Nakazawa, G.; Sangiorgi, G.; Ladich, E.; Burke, A.P.; Virmani, R. Pathology of atherosclerosis and stenting. Neuroimaging Clin. N. Am. 2007, 17, 285–301. [CrossRef]
117. Faust, O.; Acharya, U.R.; Sudarshan, V.K.; Tan, R.S.; Yeong, C.H.; Molinari, F.; Ng, K.H. Computer aided diagnosis of Coronary Artery Disease, Myocardial Infarction and carotid atherosclerosis using ultrasound images: A review. Phys. Med. 2017, 33, 1–15. [CrossRef]
118. Adams, A.; Bojara, W.; Schunk, K. Early Diagnosis and Treatment of Coronary Heart Disease in Symptomatic Subjects With Advanced Vascular Atherosclerosis of the Carotid Artery (Type III and IV b Findings Using Ultrasound). Cardiol. Res. 2017, 8, 7–12. [CrossRef]
119. Teramoto, T.; Sasaki, J.; Ishibashi, S.; Birou, S.; Daida, H.; Dohi, S.; Egusa, G.; Hiro, T.; Hirobe, K.; Iida, M.; et al. Diagnosis of atherosclerosis. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version. J. Atheroscler. Thromb. 2014, 21, 296–298. [CrossRef]
120. Mitevska, I.P.; Baneva, N.; Bosevski, M.; Kostovska, E.S. Prevalence of risk factors and asymptomatic carotid atherosclerosis in diabetic patients screened for silent myocardial ischemia by SPECT myocardial imaging. Nucl. Med. Rev. Cent. East. Eur. 2017, 20, 3–9. [CrossRef]
121. You, T.H.; Lu, Y.Q.; Tian, Z.J.; Zhou, Y.L.; Wang, T. Correlation between myocardial ischemia and carotid atherosclerosis in hypertensive patients. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30, 311–314. [PubMed]
122. Yahagi, K.; Kolodgie, F.D.; Lutter, C.; Mori, H.; Romero, M.E.; Finn, A.V.; Virmani, R. Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 191–204. [CrossRef] [PubMed]
123. Otsuka, F.; Yasuda, S.; Noguchi, T.; Ishibashi-Ueda, H. Pathology of coronary atherosclerosis and thrombosis. Cardiovasc. Diagn. Ther. 2016, 6, 396–408. [CrossRef] [PubMed]
124. Herrington, W.; Lacey, B.; Sherliker, P.; Armitage, J.; Lewington, S. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ. Res. 2016, 118, 535–546. [CrossRef]
125. Matsushita, K.; Selvin, E.; Bash, L.D.; Astor, B.C.; Coresh, J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Kidney Dis. 2010, 55, 648–659. [CrossRef]
126. Rocha, V.Z.; Santos, R.D. Subclinical carotid vascular disease and risk factors for atherosclerosis in type 1 and type 2 diabetes. Arch. Endocrinol. Metab. 2017, 61, 105–107. [CrossRef]
127. Zhang, Y.; Bai, L.; Shi, M.; Lu, H.; Wu, Y.; Tu, J.; Ni, J.; Wang, J.; Cao, L.; Lei, P.; et al. Features and risk factors of carotid atherosclerosis in a population with high stroke incidence in China. Oncotarget 2017. [CrossRef]
128. Bittner, D.O.; Klinghammer, L.; Marwan, M.; Schmid, J.; Layritz, C.; Hoffmann, U.; Achenbach, S.; Pflederer, T. Influence of Cardiovascular Risk Factors on the Prevalence of Coronary Atherosclerosis in Patients with Angiographically Normal Coronary Arteries. Acad. Radiol. 2017, 24, 580–586. [CrossRef]
129. Foteinos, G.; Hu, Y.; Xiao, Q.; Metzler, B.; Xu, Q. Rapid endothelial turnover in atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-deficient mice. Circulation 2008, 117, 1856–1863. [CrossRef]
130. Guo, F.X.; Hu, Y.W.; Zheng, L.; Wang, Q. Shear Stress in Autophagy and Its Possible Mechanisms in the Process of Atherosclerosis. DNA Cell Biol. 2017, 36, 335–346. [CrossRef]
131. Thondapu, V.; Bourantas, C.V.; Foin, N.; Jang, I.K.; Serruys, P.W.; Barlis, P. Biomechanical stress in coronary atherosclerosis: Emerging insights from computational modelling. Eur. Heart J. 2016. [CrossRef] [PubMed]
132. Schleicher, E.; Friess, U. Oxidative stress, AGE, and atherosclerosis. Kidney Int. 2007, 72, S17–S26. [CrossRef] [PubMed]
133. Villa, F.; Malovini, A.; Carrizzo, A.; Spinelli, C.C.; Ferrario, A.; Maciag, A.; Madonna, M.; Bellazzi, R.; Milanesi, L.; Vecchione, C.; et al. Serum BPIFB4 levels classify health status in long-living individuals. Immun. Ageing 2015, 12, 27. [CrossRef]
134. von Hundelshausen, P.; Weber, C. Chronic inflammation and atherosclerosis. Dtsch. Med. Wochenschr. 2013, 138, 1839–1844. [CrossRef] [PubMed]
135. Titov, V.N. Atherosclerosis as pathology of polyene fatty acids. Vestn. Ross. Akad. Med. Nauk 2001, 5, 48–53.
136. Woolf, N. Pathology of atherosclerosis. Br. Med. Bull. 1990, 46, 960–985. [CrossRef]
137. Klingenberg, R.; Matter, C.M.; Luscher, T.F. Immune cells in atherosclerosis—Good or bad? Praxis (Bern 1994) 2016, 105, 437–444. [CrossRef]
138. Schaftenaar, F.; Frodermann, V.; Kuiper, J.; Lutgens, E. Atherosclerosis: The interplay between lipids and immune cells. Curr. Opin. Lipidol. 2016, 27, 209–215. [CrossRef]
139. Tada, H.; Kawashiri, M.A.; Nohara, A.; Inazu, A.; Kobayashi, J.; Yasuda, K.; Mabuchi, H.; Yamagishi, M.; Hayashi, K. Lipid Management in a Japanese Community:Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012. J. Atheroscler. Thromb. 2017, 24, 338–345. [CrossRef]
140. Authors/Task Force, M.; Catapano, A.L.; Graham, I.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.; Landmesser, U.; et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016, 253, 281–344. [CrossRef]
141. Martinez-Abundis, E.; Mendez-Del Villar, M.; Perez-Rubio, K.G.; Zuniga, L.Y.; Cortez-Navarrete, M.; Ramirez-Rodriguez, A.; Gonzalez-Ortiz, M. Novel nutraceutic therapies for the treatment of metabolic syndrome. World J. Diabetes 2016, 7, 142–152. [CrossRef] [PubMed]
142. Fan, E.; Zhang, L.; Jiang, S.; Bai, Y. Beneficial effects of resveratrol on atherosclerosis. J. Med. Food 2008, 11, 610–614. [CrossRef] [PubMed]
143. Cho, I.J.; Ahn, J.Y.; Kim, S.; Choi, M.S.; Ha, T.Y. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 2008, 367, 190–194. [CrossRef] [PubMed]
144. Voloshyna, I.; Hussaini, S.M.; Reiss, A.B. Resveratrol in cholesterol metabolism and atherosclerosis. J. Med. Food 2012, 15, 763–773. [CrossRef] [PubMed]
145. Yashiro, T.; Nanmoku, M.; Shimizu, M.; Inoue, J.; Sato, R. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins. Atherosclerosis 2012, 220, 369–374. [CrossRef]
146. Gnoni, G.V.; Paglialonga, G. Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur. J. Clin. Investig. 2009, 39, 211–218. [CrossRef]
147. Zheng, Y.; Zhao, Z.; Wu, W.; Song, C.; Meng, S.; Fan, L.; Bing, X.; Chen, J. Effects of dietary resveratrol supplementation on hepatic and serum pro-/anti-inflammatory activity in juvenile GIFT tilapia, Oreochromis niloticus. Dev. Comp. Immunol. 2017, 73, 220–228. [CrossRef]
148. Wang, G.; Hu, Z.; Song, X.; Cui, Q.; Fu, Q.; Jia, R.; Zou, Y.; Li, L.; Yin, Z. Analgesic and Anti-Inflammatory Activities of Resveratrol through Classic Models in Mice and Rats. Evid. Based Complement. Alternat. Med. 2017, 2017, 5197567. [CrossRef]
149. Zhang, P.; Li, Y.; Du, Y.; Li, G.; Wang, L.; Zhou, F. Resveratrol Ameliorated Vascular Calcification by Regulating Sirt-1 and Nrf2. Transplant. Proc. 2016, 48, 3378–3386. [CrossRef]
150. Peredo-Escarcega, A.E.; Guarner-Lans, V.; Perez-Torres, I.; Ortega-Ocampo, S.; Carreon-Torres, E.; Castrejon-Tellez, V.; Diaz-Diaz, E.; Rubio-Ruiz, M.E. The Combination of Resveratrol and Quercetin Attenuates Metabolic Syndrome in Rats by Modifying the Serum Fatty Acid Composition and by Upregulating SIRT 1 and SIRT 2 Expression in White Adipose Tissue. Evid. Based Complement. Alternat. Med. 2015, 2015, 474032. [CrossRef]
151. Shakibaei, M.; Buhrmann, C.; Mobasheri, A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J. Biol. Chem. 2011, 286, 11492–11505. [CrossRef] [PubMed]
152. Song, R.; Li, W.Q.; Dou, J.L.; Li, L.; Hu, Y.J.; Guo, J.Z.; Lu, D.; Zhang, G.; Sun, L. Resveratrol reduces inflammatory cytokines via inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signal pathway in a rabbit atherosclerosis model. Zhonghua Xin Xue Guan Bing Za Zhi 2013, 41, 866–869. [PubMed]
153. Novaes, R.D.; Peluzio Mdo, C.; Maldonado, I.R. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq. Bras. Cardiol. 2012, 98, 571–572. [CrossRef] [PubMed]
154. Buttari, B.; Profumo, E.; Segoni, L.; D’Arcangelo, D.; Rossi, S.; Facchiano, F.; Saso, L.; Businaro, R.; Iuliano, L.; Rigano, R. Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: Potential therapeutic implications in atherosclerosis. Oxid. Med. Cell. Longev. 2014, 2014, 257543. [CrossRef]
155. Prasad, K. Resveratrol, wine, and atherosclerosis. Int. J. Angiol. 2012, 21, 7–18. [CrossRef] [PubMed]
156. Rocha, K.K.; Souza, G.A.; Seiva, F.R.; Ebaid, G.X.; Novelli, E.L. Weekend ethanol consumption and high-sucrose diet: Resveratrol effects on energy expenditure, substrate oxidation, lipid profile, oxidative stress and hepatic energy metabolism. Alcohol. Alcohol. 2011, 46, 10–16. [CrossRef]
157. Sahebkar, A. Effects of resveratrol supplementation on plasma lipids: A systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 2013, 71, 822–835. [CrossRef]
158. Bhatt, J.K.; Thomas, S.; Nanjan, M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32, 537–541. [CrossRef]
159. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R.H.; van de Weijer, T.; Goossens, G.H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S.; et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14, 612–622. [CrossRef]
160. Bo, S.; Ciccone, G.; Castiglione, A.; Gambino, R.; De Michieli, F.; Villois, P.; Durazzo, M.; Cavallo-Perin, P.; Cassader, M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr. Med. Chem. 2013, 20, 1323–1331. [CrossRef]
161. Tome-Carneiro, J.; Gonzalvez, M.; Larrosa, M.; Garcia-Almagro, F.J.; Aviles-Plaza, F.; Parra, S.; Yanez-Gascon, M.J.; Ruiz-Ros, J.A.; Garcia-Conesa, M.T.; Tomas-Barberan, F.A.; et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 2012, 56, 810–821. [CrossRef]
162. Kurosawa, T.; Itoh, F.; Nozaki, A.; Nakano, Y.; Katsuda, S.; Osakabe, N.; Tsubone, H.; Kondo, K.; Itakura, H. Suppressive effect of cocoa powder on atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits. J. Atheroscler. Thromb. 2005, 12, 20–28. [CrossRef]
163. Paramo, J.A. A new favourable effect of cocoa on atherosclerosis? Cardiovasc. Res. 2008, 79, 3–4. [CrossRef]
164. Guan, H.; Lin, Y.; Bai, L.; An, Y.; Shang, J.; Wang, Z.; Zhao, S.; Fan, J.; Liu, E. Dietary Cocoa Powder Improves Hyperlipidemia and Reduces Atherosclerosis in apoE Deficient Mice through the Inhibition of Hepatic Endoplasmic Reticulum Stress. Mediators Inflamm. 2016, 2016, 1937572. [CrossRef]
165. Pelaez-Soto, A.; Fernandez-Espinar, M.T.; Roig, P.; Gil, J.V. Evaluation of the Ability of Polyphenol Extracts of Cocoa and Red Grape to Promote the Antioxidant Response in Yeast Using a Rapid Multiwell Assay. J. Food Sci. 2017, 82, 324–332. [CrossRef]
166. Yasuda, A.; Natsume, M.; Sasaki, K.; Baba, S.; Nakamura, Y.; Kanegae, M.; Nagaoka, S. Cacao procyanidins reduce plasma cholesterol and increase fecal steroid excretion in rats fed a high-cholesterol diet. Biofactors 2008, 33, 211–223. [CrossRef]
167. Kris-Etherton, P.M.; Derr, J.A.; Mustad, V.A.; Seligson, F.H.; Pearson, T.A. Effects of a milk chocolate bar per day substituted for a high-carbohydrate snack in young men on an NCEP/AHA Step 1 Diet. Am. J. Clin. Nutr. 1994, 60 (Suppl. 6), 1037S–1042S. [CrossRef]
168. Kondo, K.; Hirano, R.; Matsumoto, A.; Igarashi, O.; Itakura, H. Inhibition of LDL oxidation by cocoa. Lancet 1996, 348, 1514. [CrossRef]
169. Mursu, J.; Voutilainen, S.; Nurmi, T.; Rissanen, T.H.; Virtanen, J.K.; Kaikkonen, J.; Nyyssonen, K.; Salonen, J.T. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic. Biol. Med. 2004, 37, 1351–1359. [CrossRef]
170. Fraga, C.G.; Actis-Goretta, L.; Ottaviani, J.I.; Carrasquedo, F.; Lotito, S.B.; Lazarus, S.; Schmitz, H.H.; Keen, C.L. Regular consumption of a flavanol-rich chocolate can improve oxidant stress in young soccer players. Clin. Dev. Immunol. 2005, 12, 11–17. [CrossRef]
171. Ludovici, V.; Barthelmes, J.; Nagele, M.P.; Enseleit, F.; Ferri, C.; Flammer, A.J.; Ruschitzka, F.; Sudano, I. Cocoa, Blood Pressure, and Vascular Function. Front. Nutr. 2017, 4, 36. [CrossRef] [PubMed]
172. Davies, M.J.; Judd, J.T.; Baer, D.J.; Clevidence, B.A.; Paul, D.R.; Edwards, A.J.; Wiseman, S.A.; Muesing, R.A.; Chen, S.C. Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J. Nutr. 2003, 133, 3298S–3302S. [CrossRef] [PubMed]
173. Zomer, E.; Owen, A.; Magliano, D.J.; Liew, D.; Reid, C.M. The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: Best case scenario analysis using a Markov model. BMJ 2012, 344, e3657. [CrossRef] [PubMed]
174. Cao, H.; Ou, J.; Chen, L.; Zhang, Y.; Szkudelski, T.; Delmas, D.; Daglia, M.; Xiao, J. Dietary polyphenols and type 2 diabetes: Human Study and Clinical Trial. Crit. Rev. Food Sci. Nutr. 2019, 59, 3371–3379. [CrossRef]
175. Bhaskar, S.; Kumar, K.S.; Krishnan, K.; Antony, H. Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition 2013, 29, 219–229. [CrossRef]
176. Schulz, H.U.; Schurer, M.; Bassler, D.; Weiser, D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung 2005, 55, 561–568. [CrossRef]
177. Xue, F.; Nie, X.; Shi, J.; Liu, Q.; Wang, Z.; Li, X.; Zhou, J.; Su, J.; Xue, M.; Chen, W.D.; et al. Quercetin Inhibits LPS-Induced Inflammation and ox-LDL-Induced Lipid Deposition. Front. Pharmacol. 2017, 8, 40. [CrossRef]
178. Mbikay, M.; Sirois, F.; Simoes, S.; Mayne, J.; Chretien, M. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio 2014, 4, 755–762. [CrossRef]
179. Kaur, G.; Meena, C. Amelioration of obesity, glucose intolerance, and oxidative stress in high-fat diet and low-dose streptozotocin-induced diabetic rats by combination consisting of “curcumin with piperine and quercetin”. ISRN Pharmacol. 2012, 2012, 957283. [CrossRef]
180. Lu, X.L.; Zhao, C.H.; Yao, X.L.; Zhang, H. Quercetin attenuates high fructose feeding-induced atherosclerosis by suppressing inflammation and apoptosis via ROS-regulated PI3K/AKT signaling pathway. Biomed. Pharmacother. 2017, 85, 658–671. [CrossRef]
181. Kleemann, R.; Verschuren, L.; Morrison, M.; Zadelaar, S.; van Erk, M.J.; Wielinga, P.Y.; Kooistra, T. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011, 218, 44–52. [CrossRef] [PubMed]
182. Hung, C.H.; Chan, S.H.; Chu, P.M.; Tsai, K.L. Quercetin is a potent anti-atherosclerotic compound by activation of SIRT1 signaling under oxLDL stimulation. Mol. Nutr. Food Res. 2015, 59, 1905–1917. [CrossRef] [PubMed]
183. Xiao, L.; Liu, L.; Guo, X.; Zhang, S.; Wang, J.; Zhou, F.; Liu, L.; Tang, Y.; Yao, P. Quercetin attenuates high fat diet-induced atherosclerosis in apolipoprotein E knockout mice: A critical role of NADPH oxidase. Food Chem. Toxicol. 2017, 105, 22–33. [CrossRef] [PubMed]
184. Talirevic, E.; Jelena, S. Quercetin in the treatment of dyslipidemia. Med. Arh. 2012, 66, 87–88. [CrossRef] [PubMed]
185. Sahebkar, A. Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2017, 57, 666–676. [CrossRef]
186. Boots, A.W.; Haenen, G.R.; Bast, A. Health effects of quercetin: From antioxidant to nutraceutical. Eur. J. Pharmacol. 2008, 585, 325–337. [CrossRef]
187. Pawar, Y.B.; Munjal, B.; Arora, S.; Karwa, M.; Kohli, G.; Paliwal, J.K.; Bansal, A.K. Bioavailability of a lipidic formulation of curcumin in healthy human volunteers. Pharmaceutics 2012, 4, 517–530. [CrossRef]
188. Cox, K.H.; Pipingas, A.; Scholey, A.B. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J. Psychopharmacol. 2015, 29, 642–651. [CrossRef]
189. Vareed, S.K.; Kakarala, M.; Ruffin, M.T.; Crowell, J.A.; Normolle, D.P.; Djuric, Z.; Brenner, D.E. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomark. Prev. 2008, 17, 1411–1417. [CrossRef]
190. Strimpakos, A.S.; Sharma, R.A. Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signal. 2008, 10, 511–545. [CrossRef]
191. Kumar, A.; Cannon, C.P. Acute coronary syndromes: Diagnosis and management, part I. Mayo Clin. Proc. 2009, 84, 917–938. [CrossRef]
192. Alwi, I.; Santoso, T.; Suyono, S.; Sutrisna, B.; Suyatna, F.D.; Kresno, S.B.; Ernie, S. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med. Indones. 2008, 40, 201–210.
193. Azhdari, M.; Karandish, M.; Mansoori, A. Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Phytother. Res. 2019, 33, 1289–1301. [CrossRef] [PubMed]
194. Saraf-Bank, S.; Ahmadi, A.; Paknahad, Z.; Maracy, M.; Nourian, M. Effects of curcumin on cardiovascular risk factors in obese and overweight adolescent girls: A randomized clinical trial. Sao Paulo Med. J. 2019, 137, 414–422. [CrossRef]
195. Banez, M.J.; Geluz, M.I.; Chandra, A.; Hamdan, T.; Biswas, O.S.; Bryan, N.S.; Von Schwarz, E.R. A systemic review on the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human cardiovascular health. Nutr. Res. 2020, 78, 11–26. [CrossRef] [PubMed]
196. Sundar Dhilip Kumar, S.; Houreld, N.N.; Abrahamse, H. Therapeutic Potential and Recent Advances of Curcumin in the Treatment of Aging-Associated Diseases. Molecules 2018, 23, 835. [CrossRef]
197. Simental-Mendia, L.E.; Pirro, M.; Gotto, A.M., Jr.; Banach, M.; Atkin, S.L.; Majeed, M.; Sahebkar, A. Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2019, 59, 1178–1187. [CrossRef]
198. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell. Mol. Life Sci. 2008, 65, 1631–1652. [CrossRef]
199. Wu, M.; Wang, J. Advance on study in anti-atherosclerosis mechanism of berberine. Zhongguo Zhong Yao Za Zhi 2008, 33, 2013–2016. [CrossRef]
200. Wu, M.; Wang, J.; Liu, L.T. Advance of studies on anti-atherosclerosis mechanism of berberine. Chin. J. Integr. Med. 2010, 16, 188–192. [CrossRef] [PubMed]
201. Feng, M.; Zou, Z.; Zhou, X.; Hu, Y.; Ma, H.; Xiao, Y.; Li, X.; Ye, X. Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE-/-mice. Int. Immunopharmacol. 2017, 43, 195–202. [CrossRef]
202. Wang, Q.; Zhang, M.; Liang, B.; Shirwany, N.; Zhu, Y.; Zou, M.H. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: The role of uncoupling protein 2. PLoS ONE 2011, 6, e25436. [CrossRef] [PubMed]
203. Li, K.; Yao, W.; Zheng, X.; Liao, K. Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage. Cell Res. 2009, 19, 1006–1017. [CrossRef] [PubMed]
204. Cicero, A.F.; Rovati, L.C.; Setnikar, I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 2007, 57, 26–30. [CrossRef] [PubMed]
205. Kong, W.J.; Wei, J.; Zuo, Z.Y.; Wang, Y.M.; Song, D.Q.; You, X.F.; Zhao, L.X.; Pan, H.N.; Jiang, J.D. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 2008, 57, 1029–1037. [CrossRef] [PubMed]
206. Kong, W.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Li, C.; Wang, Y.; Wang, Z.; Si, S.; Pan, H.; et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10, 1344–1351. [CrossRef]
207. Zhao, W.; Xue, R.; Zhou, Z.X.; Kong, W.J.; Jiang, J.D. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed. Pharmacother. 2008, 62, 730–731. [CrossRef]
208. Persico, M.; Masarone, M.; Damato, A.; Ambrosio, M.; Federico, A.; Rosato, V.; Bucci, T.; Carrizzo, A.; Vecchione, C. Non alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterol. 2017, 17, 35. [CrossRef]
209. An, S.; Han, J.I.; Kim, M.J.; Park, J.S.; Han, J.M.; Baek, N.I.; Chung, H.G.; Choi, M.S.; Lee, K.T.; Jeong, T.S. Ethanolic extracts of Brassica campestris spp. rapa roots prevent high-fat diet-induced obesity via beta(3)-adrenergic regulation of white adipocyte lipolytic activity. J. Med. Food 2010, 13, 406–414. [CrossRef]
210. Palomaki, A.; Pohjantahti-Maaroos, H.; Wallenius, M.; Kankkunen, P.; Aro, H.; Husgafvel, S.; Pihlava, J.M.; Oksanen, K. Effects of dietary cold-pressed turnip rapeseed oil and butter on serum lipids, oxidized LDL and arterial elasticity in men with metabolic syndrome. Lipids Health Dis. 2010, 9, 137. [CrossRef]
211. Vo, T.S.; Kim, S.K. Down-regulation of histamine-induced endothelial cell activation as potential anti-atherosclerotic activity of peptides from Spirulina maxima. Eur. J. Pharm. Sci. 2013, 50, 198–207. [CrossRef] [PubMed]
212. Cheong, S.H.; Kim, M.Y.; Sok, D.E.; Hwang, S.Y.; Kim, J.H.; Kim, H.R.; Lee, J.H.; Kim, Y.B.; Kim, M.R. Spirulina prevents atherosclerosis by reducing hypercholesterolemia in rabbits fed a high-cholesterol diet. J. Nutr. Sci. Vitaminol. (Tokyo) 2010, 56, 34–40. [CrossRef] [PubMed]
213. Sengupta, S.; Koley, H.; Dutta, S.; Bhowal, J. Hypocholesterolemic effect of Spirulina platensis (SP) fortified functional soy yogurts on diet-induced hypercholesterolemia. J. Funct. Foods 2018, 48, 54–64. [CrossRef]
214. Szulinska, M.; Gibas-Dorna, M.; Miller-Kasprzak, E.; Suliburska, J.; Miczke, A.; Walczak-Galezewska, M.; Stelmach-Mardas, M.; Walkowiak, J.; Bogdanski, P. Spirulina maxima improves insulin sensitivity, lipid profile, and total antioxidant status in obese patients with well-treated hypertension: A randomized double-blind placebo-controlled study. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 2473–2481. [PubMed]
215. Hamedifard, Z.; Milajerdi, A.; Reiner, Z.; Taghizadeh, M.; Kolahdooz, F.; Asemi, Z. The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Phytother. Res. 2019, 33, 2609–2621. [CrossRef]
216. Hernandez-Lepe, M.A.; Wall-Medrano, A.; Lopez-Diaz, J.A.; Juarez-Oropeza, M.A.; Hernandez-Torres, R.P.; Ramos-Jimenez, A. Hypolipidemic Effect of Arthrospira (Spirulina) maxima Supplementation and a Systematic Physical Exercise Program in Overweight and Obese Men: A Double-Blind, Randomized, and Crossover Controlled Trial. Mar. Drugs 2019, 17, 270. [CrossRef] [PubMed]
217. Hernandez-Lepe, M.A.; Olivas-Aguirre, F.J.; Gomez-Miranda, L.M.; Hernandez-Torres, R.P.; Manriquez-Torres, J.J.; Ramos-Jimenez, A. Systematic Physical Exercise and Spirulina maxima Supplementation Improve Body Composition, Cardiorespiratory Fitness, and Blood Lipid Profile: Correlations of a Randomized Double-Blind Controlled Trial. Antioxidants 2019, 8, 507. [CrossRef]
218. Serban, M.C.; Sahebkar, A.; Dragan, S.; Stoichescu-Hogea, G.; Ursoniu, S.; Andrica, F.; Banach, M. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations. Clin. Nutr. 2016, 35, 842–851. [CrossRef]
219. Park, H.J.; Lee, Y.J.; Ryu, H.K.; Kim, M.H.; Chung, H.W.; Kim, W.Y. A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans. Ann. Nutr. Metab. 2008, 52, 322–328. [CrossRef]
220. Mazokopakis, E.E.; Starakis, I.K.; Papadomanolaki, M.G.; Mavroeidi, N.G.; Ganotakis, E.S. The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: A prospective study. J. Sci. Food Agric. 2014, 94, 432–437. [CrossRef]
221. Wasson, S.; Fleming, D.; Reddy, H.K. Pathology, prognosis, and prevention of heart failure. Mo. Med. 2005, 102, 480–484. [PubMed]
222. Braam, R.L.; Gaillard, C.A. Heart failure: Chapter 3. Underlying pathology in heart failure ‘Failure of the circulation versus failure of the heart’. Neth. Heart J. 2004, 12, 303–307. [PubMed]
223. Izzo, C.; Carrizzo, A.; Alfano, A.; Virtuoso, N.; Capunzo, M.; Calabrese, M.; De Simone, E.; Sciarretta, S.; Frati, G.; Oliveti, M.; et al. The Impact of Aging on Cardio and Cerebrovascular Diseases. Int. J. Mol. Sci. 2018, 19, 481. [CrossRef] [PubMed]
224. Kajita, A. Pathology of heart failure. Kyobu Geka 1971, 24, 100–106.
225. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Colvin, M.M.; Drazner, M.H.; Filippatos, G.S.; Fonarow, G.C.; Givertz, M.M.; et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Card. Fail. 2017. [CrossRef]
226. Swedberg, K. Guidelines for the treatment of chronic heart failure. Trends Cardiovasc. Med. 2017. [CrossRef]
227. Wang, G.Y.; Wang, Y.M.; Zhang, L.N.; Li, Q.; Yue, H.; Song, C.M.; Feng, J.K.; Wang, N. Effect of resveratrol on heart function of rats with adriamycin-induced heart failure. Zhongguo Zhong Yao Za Zhi 2007, 32, 1563–1565.
228. Xuan, W.; Wu, B.; Chen, C.; Chen, B.; Zhang, W.; Xu, D.; Bin, J.; Liao, Y. Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*. Crit. Care Med. 2012, 40, 3026–3033. [CrossRef]
229. Gu, X.S.; Wang, Z.B.; Ye, Z.; Lei, J.P.; Li, L.; Su, D.F.; Zheng, X. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet. Mol. Res. 2014, 13, 323–335. [CrossRef]
230. Gupta, P.K.; DiPette, D.J.; Supowit, S.C. Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci. Nutr. 2014, 2, 218–229. [CrossRef]
231. Ahmet, I.; Tae, H.J.; Lakatta, E.G.; Talan, M. Long-term low dose dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in chronic heart failure in rats. Can. J. Physiol. Pharmacol. 2017, 95, 268–274. [CrossRef] [PubMed]
232. Sung, M.M.; Byrne, N.J.; Robertson, I.M.; Kim, T.T.; Samokhvalov, V.; Levasseur, J.; Soltys, C.L.; Fung, D.; Tyreman, N.; Denou, E.; et al. Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure. Am. J. Physiol. Heart Circ. Physiol. 2017, 312, H842–H853. [CrossRef] [PubMed]
233. Riba, A.; Deres, L.; Sumegi, B.; Toth, K.; Szabados, E.; Halmosi, R. Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model. Oxid. Med. Cell. Longev. 2017, 2017, 6819281. [CrossRef] [PubMed]
234. Raj, P.; Louis, X.L.; Thandapilly, S.J.; Movahed, A.; Zieroth, S.; Netticadan, T. Potential of resveratrol in the treatment of heart failure. Life Sci. 2014, 95, 63–71. [CrossRef] [PubMed]
235. Sung, M.M.; Dyck, J.R. Therapeutic potential of resveratrol in heart failure. Ann. N. Y. Acad. Sci. 2015, 1348, 32–45. [CrossRef]
236. Magyar, K.; Halmosi, R.; Palfi, A.; Feher, G.; Czopf, L.; Fulop, A.; Battyany, I.; Sumegi, B.; Toth, K.; Szabados, E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 2012, 50, 179–187. [CrossRef] [PubMed]
237. Militaru, C.; Donoiu, I.; Craciun, A.; Scorei, I.D.; Bulearca, A.M.; Scorei, R.I. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013, 29, 178–183. [CrossRef]
238. Taub, P.R.; Ramirez-Sanchez, I.; Ciaraldi, T.P.; Perkins, G.; Murphy, A.N.; Naviaux, R.; Hogan, M.; Maisel, A.S.; Henry, R.R.; Ceballos, G.; et al. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: Effects of epicatechin rich cocoa. Clin. Transl. Sci. 2012, 5, 43–47. [CrossRef]
239. Taub, P.R.; Ramirez-Sanchez, I.; Ciaraldi, T.P.; Gonzalez-Basurto, S.; Coral-Vazquez, R.; Perkins, G.; Hogan, M.; Maisel, A.S.; Henry, R.R.; Ceballos, G.; et al. Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: Restorative effects of (-)-epicatechin-rich cocoa. Clin. Sci. 2013, 125, 383–389. [CrossRef]
240. Ramirez-Sanchez, I.; Taub, P.R.; Ciaraldi, T.P.; Nogueira, L.; Coe, T.; Perkins, G.; Hogan, M.; Maisel, A.S.; Henry, R.R.; Ceballos, G.; et al. (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. Int. J. Cardiol. 2013, 168, 3982–3990. [CrossRef]
241. Grassi, D.; Desideri, G.; Necozione, S.; Lippi, C.; Casale, R.; Properzi, G.; Blumberg, J.B.; Ferri, C. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J. Nutr. 2008, 138, 1671–1676. [CrossRef]
242. De Palma, R.; Sotto, I.; Wood, E.G.; Khan, N.Q.; Butler, J.; Johnston, A.; Rothman, M.T.; Corder, R. Cocoa flavanols reduce N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. ESC Heart Fail. 2016, 3, 97–106. [CrossRef] [PubMed]
243. Gong, F.; Yao, S.; Wan, J.; Gan, X. Chocolate Consumption and Risk of Heart Failure: A Meta-Analysis of Prospective Studies. Nutrients 2017, 9, 402. [CrossRef] [PubMed]
244. Larson, A.J.; Symons, J.D.; Jalili, T. Therapeutic potential of quercetin to decrease blood pressure: Review of efficacy and mechanisms. Adv. Nutr. 2012, 3, 39–46. [CrossRef] [PubMed]
245. Hertog, M.G.; Feskens, E.J.; Hollman, P.C.; Katan, M.B.; Kromhout, D. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet 1993, 342, 1007–1011. [CrossRef]
246. Huxley, R.R.; Neil, H.A. The relation between dietary flavonol intake and coronary heart disease mortality: A meta-analysis of prospective cohort studies. Eur. J. Clin. Nutr. 2003, 57, 904–908. [CrossRef] [PubMed]
247. Morimoto, T.; Sunagawa, Y.; Kawamura, T.; Takaya, T.; Wada, H.; Nagasawa, A.; Komeda, M.; Fujita, M.; Shimatsu, A.; Kita, T.; et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Investig. 2008, 118, 868–878. [CrossRef]
248. Tang, Y.H.; Bao, M.W.; Yang, B.; Zhang, Y.; Zhang, B.S.; Zhou, Q.; Chen, J.L.; Huang, C.X. Curcumin attenuates left ventricular dysfunction and remodeling in rabbits with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2009, 37, 262–267.
249. Wongcharoen, W.; Jai-Aue, S.; Phrommintikul, A.; Nawarawong, W.; Woragidpoonpol, S.; Tepsuwan, T.; Sukonthasarn, A.; Apaijai, N.; Chattipakorn, N. Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting. Am. J. Cardiol. 2012, 110, 40–44. [CrossRef]
250. Campbell, M.S.; Ouyang, A.; Krishnakumar, I.M.; Charnigo, R.J.; Westgate, P.M.; Fleenor, B.S. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial. Nutrition 2019, 62, 135–139. [CrossRef]
251. Dastani, M.; Bigdelu, L.; Hoseinzadeh, M.; Rahimi, H.R.; Karimani, A.; Hooshang Mohammadpour, A.; Salari, M. The effects of curcumin on the prevention of atrial and ventricular arrhythmias and heart failure in patients with unstable angina: A randomized clinical trial. Avicenna J. Phytomed. 2019, 9, 1–9. [PubMed]
252. Li, Y.; Chen, X.; Liu, H.; Luo, F.; Li, G. Effects of ginseng total saponins with berberine on plasma brain natriuretic peptide and Ca2+ concentration in experimental rats with chronic congestive heart failure. Zhongguo Zhong Yao Za Zhi 2009, 34, 324–327. [PubMed]
253. Zhang, X.D.; Ren, H.M.; Liu, L. Effects of different dose berberine on hemodynamic parameters and [Ca2+]i of cardiac myocytes of diastolic heart failure rat model. Zhongguo Zhong Yao Za Zhi 2008, 33, 818–821. [PubMed]
254. Marin-Neto, J.A.; Maciel, B.C.; Secches, A.L.; Gallo Junior, L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin. Cardiol. 1988, 11, 253–260. [CrossRef] [PubMed]
255. Zeng, X.H.; Zeng, X.J.; Li, Y.Y. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2003, 92, 173–176. [CrossRef]
256. Zhou, Z.; Xu, J.; Lan, T. Protective effect of berberine on isolated perfused heart in heart failure. Hua Xi Yi Ke Da Xue Xue Bao 2001, 32, 417–418.
257. Zeng, X.; Zeng, X. Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC. Biomed. Chromatogr. 1999, 13, 442–444. [CrossRef]
258. Khan, M.; Shobha, J.C.; Mohan, I.K.; Naidu, M.U.; Sundaram, C.; Singh, S.; Kuppusamy, P.; Kutala, V.K. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity. Phytother. Res. 2005, 19, 1030–1037. [CrossRef]
259. Ionov, V.A.; Basova, M.M. Use of blue-green micro-seaweed Spirulina platensis for the correction of lipid and hemostatic disturbances in patients with ischemic heart disease. Vopr. Pitan. 2003, 72, 28–31.
260. Kerner, W.; Bruckel, J.; German Diabetes, A. Definition, classification and diagnosis of diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2014, 122, 384–386. [CrossRef]
261. American Diabetes, A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014, 37 (Suppl. 1), S81–S90. [CrossRef]
262. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26 (Suppl. 1), S5–S20.
263. Ammon, H.P. Molecular pathology of diabetes mellitus. The effects of insulin. Pharm. Unserer Zeit 2001, 30, 21–26. [CrossRef]
264. Fujii, A. Pathology of diabetes mellitus. Nihon Rinsho 2002, 60 (Suppl. 8), 131–136.
265. Ametov, A.S.; Kochergina, I.I.; Ulanova, K.A. Effect of insulin therapy on insulin resistance and risk for ischemic heart disease and death from cardiovascular pathology in patients with diabetes mellitus, type 2. Terapevticheskii Arkhiv 2010, 82, 42–46. [PubMed]
266. Levy, B.I.; Schiffrin, E.L.; Mourad, J.J.; Agostini, D.; Vicaut, E.; Safar, M.E.; Struijker-Boudier, H.A. Impaired tissue perfusion: A pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008, 118, 968–976. [CrossRef]
267. Sadzeviciene, R.; Paipaliene, P.; Zekonis, G.; Zilinskas, J. The influence of microvascular complications caused by diabetes mellitus on the inflammatory pathology of periodontal tissues. Stomatologija 2005, 7, 121–124. [PubMed]
268. Younis, B.B.; Arshad, R.; Yousuf, H.; Salman, F.; Masood, J.; Khurshid, S. Impact of type 2 diabetes mellitus on quality of life in people with diabetespresenting to a specialist diabetes clinic. Turk. J. Med. Sci. 2017, 47, 123–126. [CrossRef]
269. Teuscher, A.; Richterich, R. New Swiss guide lines for the diagnosis of diabetes mellitus. Schweiz. Med. Wochenschr. 1971, 101, 390.
270. Martinka, E. Comments on current guidelines of type 2 diabetes mellitus treatment. Vnitr. Lek. 2017, 63, 211–217.
271. Yang, T.; Wang, L.; Zhu, M.; Zhang, L.; Yan, L. Properties and molecular mechanisms of resveratrol: A review. Pharmazie 2015, 70, 501–506. [PubMed]
272. Vallianou, N.G.; Evangelopoulos, A.; Kazazis, C. Resveratrol and diabetes. Rev. Diabet. Stud. 2013, 10, 236–242. [CrossRef] [PubMed]
273. Szkudelska, K.; Szkudelski, T. Resveratrol, obesity and diabetes. Eur. J. Pharmacol. 2010, 635, 1–8. [CrossRef] [PubMed]
274. Shen, L.L.; Wang, X.M.; He, B.L. Advance of resveratrol in treating diabetes mellitus. Zhongguo Zhong Xi Yi Jie He Za Zhi 2013, 33, 279–281. [PubMed]
275. Ren, Z.; Wang, L.; Cui, J.; Huoc, Z.; Xue, J.; Cui, H.; Mao, Q.; Yang, R. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie 2013, 68, 689–694.
276. Pan, W.; Yu, H.; Huang, S.; Zhu, P. Resveratrol Protects against TNF-alpha-Induced Injury in Human Umbilical Endothelial Cells through Promoting Sirtuin-1-Induced Repression of NF-KB and p38 MAPK. PLoS ONE 2016, 11, e0147034. [CrossRef]
277. Sadeghi, A.; Seyyed Ebrahimi, S.S.; Golestani, A.; Meshkani, R. Resveratrol Ameliorates Palmitate-Induced Inflammation in Skeletal Muscle Cells by Attenuating Oxidative Stress and JNK/NF-KB Pathway in a SIRT1-Independent Mechanism. J. Cell. Biochem. 2017. [CrossRef]
278. Wang, X.; Buechler, N.L.; Yoza, B.K.; McCall, C.E.; Vachharajani, V.T. Resveratrol attenuates microvascular inflammation in sepsis via SIRT-1-Induced modulation of adhesion molecules in ob/ob mice. Obesity 2015, 23, 1209–1217. [CrossRef]
279. Liu, C.W.; Sung, H.C.; Lin, S.R.; Wu, C.W.; Lee, C.W.; Lee, I.T.; Yang, Y.F.; Yu, I.S.; Lin, S.W.; Chiang, M.H.; et al. Resveratrol attenuates ICAM-1 expression and monocyte adhesiveness to TNF-alpha-treated endothelial cells: Evidence for an anti-inflammatory cascade mediated by the miR-221/222/AMPK/p38/NF-kappaB pathway. Sci. Rep. 2017, 7, 44689. [CrossRef]
280. Wang, X.H.; Zhu, L.; Hong, X.; Wang, Y.T.; Wang, F.; Bao, J.P.; Xie, X.H.; Liu, L.; Wu, X.T. Resveratrol attenuated TNF-alpha-induced MMP-3 expression in human nucleus pulposus cells by activating autophagy via AMPK/SIRT1 signaling pathway. Exp. Biol. Med. 2016, 241, 848–853. [CrossRef] [PubMed]
281. Zhou, D.Y.; Su, Y.; Gao, P.; Yang, Q.H.; Wang, Z.; Xu, Q. Resveratrol ameliorates high glucose-induced oxidative stress injury in human umbilical vein endothelial cells by activating AMPK. Life Sci. 2015, 136, 94–99. [CrossRef] [PubMed]
282. Caggiano, R.; Cattaneo, F.; Moltedo, O.; Esposito, G.; Perrino, C.; Trimarco, B.; Ammendola, R.; Faraonio, R. miR-128 Is Implicated in Stress Responses by Targeting MAFG in Skeletal Muscle Cells. Oxid. Med. Cell. Longev. 2017, 2017, 9308310. [CrossRef] [PubMed]
283. Faraonio, R.; Vergara, P.; Marzo, D.D.; Napolitano, M.; Russo, T.; Cimino, F. Transcription regulation in NIH3T3 cell clones resistant to diethylmaleate-induced oxidative stress and apoptosis. Antioxid. Redox Signal. 2006, 8, 365–374. [CrossRef] [PubMed]
284. Szkudelski, T.; Szkudelska, K. Resveratrol and diabetes: From animal to human studies. Biochim. Biophys. Acta 2015, 1852, 1145–1154. [CrossRef]
285. Bo, S.; Ponzo, V.; Evangelista, A.; Ciccone, G.; Goitre, I.; Saba, F.; Procopio, M.; Cassader, M.; Gambino, R. Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: A double-blind randomized controlled trial. Acta Diabetol. 2017, 54, 499–507. [CrossRef]
286. Timmers, S.; de Ligt, M.; Phielix, E.; van de Weijer, T.; Hansen, J.; Moonen-Kornips, E.; Schaart, G.; Kunz, I.; Hesselink, M.K.; Schrauwen-Hinderling, V.B.; et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2016, 39, 2211–2217. [CrossRef]
287. Hoseini, A.; Namazi, G.; Farrokhian, A.; Reiner, Z.; Aghadavod, E.; Bahmani, F.; Asemi, Z. The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Food Funct. 2019, 10, 6042–6051. [CrossRef]
288. Movahed, A.; Nabipour, I.; Lieben Louis, X.; Thandapilly, S.J.; Yu, L.; Kalantarhormozi, M.; Rekabpour, S.J.; Netticadan, T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement. Alternat. Med. 2013, 2013, 851267. [CrossRef]
289. Brasnyo, P.; Molnar, G.A.; Mohas, M.; Marko, L.; Laczy, B.; Cseh, J.; Mikolas, E.; Szijarto, I.A.; Merei, A.; Halmai, R.; et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106, 383–389. [CrossRef]
290. van der Made, S.M.; Plat, J.; Mensink, R.P. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: A randomized, placebo-controlled crossover trial. PLoS ONE 2015, 10, e0118393. [CrossRef]
291. Liu, K.; Zhou, R.; Wang, B.; Mi, M.T. Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 2014, 99, 1510–1519. [CrossRef] [PubMed]
292. Bashmakov, Y.K.; Assaad-Khalil, S.H.; Abou Seif, M.; Udumyan, R.; Megallaa, M.; Rohoma, K.H.; Zeitoun, M.; Petyaev, I.M. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol. 2014, 2014, 816307. [CrossRef] [PubMed]
293. Zhao, P.; Sui, B.D.; Liu, N.; Lv, Y.J.; Zheng, C.X.; Lu, Y.B.; Huang, W.T.; Zhou, C.H.; Chen, J.; Pang, D.L.; et al. Anti-aging pharmacology in cutaneous wound healing: Effects of metformin, resveratrol, and rapamycin by local application. Aging Cell 2017, 16, 1083–1093. [CrossRef]
294. Yaman, I.; Derici, H.; Kara, C.; Kamer, E.; Diniz, G.; Ortac, R.; Sayin, O. Effects of resveratrol on incisional wound healing in rats. Surg. Today 2013, 43, 1433–1438. [CrossRef] [PubMed]
295. Saldanha, J.F.; Leal Vde, O.; Stenvinkel, P.; Carraro-Eduardo, J.C.; Mafra, D. Resveratrol: Why is it a promising therapy for chronic kidney disease patients? Oxid. Med. Cell. Longev. 2013, 2013, 963217. [CrossRef]
296. Grassi, D.; Desideri, G.; Mai, F.; Martella, L.; De Feo, M.; Soddu, D.; Fellini, E.; Veneri, M.; Stamerra, C.A.; Ferri, C. Cocoa, glucose tolerance, and insulin signaling: Cardiometabolic protection. J. Agric. Food Chem. 2015, 63, 9919–9926. [CrossRef]
297. Stote, K.S.; Clevidence, B.A.; Novotny, J.A.; Henderson, T.; Radecki, S.V.; Baer, D.J. Effect of cocoa and green tea on biomarkers of glucose regulation, oxidative stress, inflammation and hemostasis in obese adults at risk for insulin resistance. Eur. J. Clin. Nutr. 2012, 66, 1153–1159. [CrossRef]
298. Cordero-Herrera, I.; Martin, M.A.; Goya, L.; Ramos, S. Cocoa flavonoids attenuate high glucose-induced insulin signalling blockade and modulate glucose uptake and production in human HepG2 cells. Food Chem. Toxicol. 2014, 64, 10–19. [CrossRef]
299. Cordero-Herrera, I.; Martin, M.A.; Bravo, L.; Goya, L.; Ramos, S. Cocoa flavonoids improve insulin signalling and modulate glucose production via AKT and AMPK in HepG2 cells. Mol. Nutr. Food Res. 2013, 57, 974–985. [CrossRef]
300. Martin, M.A.; Serrano, A.B.; Ramos, S.; Pulido, M.I.; Bravo, L.; Goya, L. Cocoa flavonoids up-regulate antioxidant enzyme activity via the ERK1/2 pathway to protect against oxidative stress-induced apoptosis in HepG2 cells. J. Nutr. Biochem. 2010, 21, 196–205. [CrossRef]
301. Grassi, D.; Lippi, C.; Necozione, S.; Desideri, G.; Ferri, C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am. J. Clin. Nutr. 2005, 81, 611–614. [CrossRef] [PubMed]
302. Almoosawi, S.; Tsang, C.; Ostertag, L.M.; Fyfe, L.; Al-Dujaili, E.A. Differential effect of polyphenol-rich dark chocolate on biomarkers of glucose metabolism and cardiovascular risk factors in healthy, overweight and obese subjects: A randomized clinical trial. Food Funct. 2012, 3, 1035–1043. [CrossRef] [PubMed]
303. Curtis, P.J.; Adamson, A.J.; Mathers, J.C. Effects on nutrient intake of a family-based intervention to promote increased consumption of low-fat starchy foods through education, cooking skills and personalised goal setting: The Family Food and Health Project. Br. J. Nutr. 2012, 107, 1833–1844. [CrossRef] [PubMed]
304. Curtis, P.J.; Sampson, M.; Potter, J.; Dhatariya, K.; Kroon, P.A.; Cassidy, A. Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year CVD risk in medicated postmenopausal women with type 2 diabetes: A 1-year, double-blind, randomized, controlled trial. Diabetes Care 2012, 35, 226–232. [CrossRef] [PubMed]
305. Haghighat, N.; Vafa, M.; Eghtesadi, S.; Heidari, I.; Hosseini, A.; Rostami, A. The Effects of Tocotrienols Added to Canola Oil on Microalbuminuria, Inflammation, and Nitrosative Stress in Patients with Type 2 Diabetes: A Randomized, Double-blind, Placebo-controlled Trial. Int. J. Prev. Med. 2014, 5, 617–623. [PubMed]
306. Zeng, G.; Nystrom, F.H.; Ravichandran, L.V.; Cong, L.N.; Kirby, M.; Mostowski, H.; Quon, M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000, 101, 1539–1545. [CrossRef]
307. Kim, J.H.; Kang, M.J.; Choi, H.N.; Jeong, S.M.; Lee, Y.M.; Kim, J.I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr. Res. Pract. 2011, 5, 107–111. [CrossRef]
308. Coskun, O.; Kanter, M.; Korkmaz, A.; Oter, S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol. Res. 2005, 51, 117–123. [CrossRef]
309. Stewart, L.K.; Wang, Z.; Ribnicky, D.; Soileau, J.L.; Cefalu, W.T.; Gettys, T.W. Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of C57BL/6J mice during the development of diet-induced obesity. Diabetologia 2009, 52, 514–523. [CrossRef]
310. Eid, H.M.; Nachar, A.; Thong, F.; Sweeney, G.; Haddad, P.S. The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes. Pharmacogn. Mag. 2015, 11, 74–81. [CrossRef]
311. Askari, G.; Ghiasvand, R.; Feizi, A.; Ghanadian, S.M.; Karimian, J. The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J. Res. Med. Sci. 2012, 17, 637–641. [PubMed]
312. Panchal, S.K.; Poudyal, H.; Brown, L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J. Nutr. 2012, 142, 1026–1032. [CrossRef] [PubMed]
313. Knekt, P.; Kumpulainen, J.; Jarvinen, R.; Rissanen, H.; Heliovaara, M.; Reunanen, A.; Hakulinen, T.; Aromaa, A. Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 2002, 76, 560–568. [CrossRef] [PubMed]
314. Song, Y.; Manson, J.E.; Buring, J.E.; Sesso, H.D.; Liu, S. Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic inflammation in women: A prospective study and cross-sectional analysis. J. Am. Coll. Nutr. 2005, 24, 376–384. [CrossRef]
315. Hajavi, J.; Abbas Momtazi, A.; Johnston, T.P.; Banach, M.; Majeed, M.; Sahebkar, A. Curcumin: A naturally occurring modulator of adipokines in diabetes. J. Cell. Biochem. 2017. [CrossRef]
316. Nabavi, S.F.; Thiagarajan, R.; Rastrelli, L.; Daglia, M.; Sobarzo-Sanchez, E.; Alinezhad, H.; Nabavi, S.M. Curcumin: A natural product for diabetes and its complications. Curr. Top. Med. Chem. 2015, 15, 2445–2455. [CrossRef]
317. Ghosh, S.; Banerjee, S.; Sil, P.C. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem. Toxicol. 2015, 83, 111–124. [CrossRef]
318. Wongeakin, N.; Bhattarakosol, P.; Patumraj, S. Molecular mechanisms of curcumin on diabetes-induced endothelial dysfunctions: Txnip, ICAM-1, and NOX2 expressions. BioMed Res. Int. 2014, 2014, 161346. [CrossRef]
319. Zhang, D.W.; Fu, M.; Gao, S.H.; Liu, J.L. Curcumin and diabetes: A systematic review. Evid. Based Complement. Alternat. Med. 2013, 2013, 636053. [CrossRef]
320. Meng, B.; Li, J.; Cao, H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr. Pharm. Des. 2013, 19, 2101–2113.
321. Rungseesantivanon, S.; Thenchaisri, N.; Ruangvejvorachai, P.; Patumraj, S. Curcumin supplementation could improve diabetes-induced endothelial dysfunction associated with decreased vascular superoxide production and PKC inhibition. BMC Complement. Altern. Med. 2010, 10, 57. [CrossRef] [PubMed]
322. Weisberg, S.P.; Leibel, R.; Tortoriello, D.V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149, 3549–3558. [CrossRef] [PubMed]
323. Oharomari, L.K.; de Moraes, C.; Navarro, A.M. Exercise Training but not Curcumin Supplementation Decreases Immune Cell Infiltration in the Pancreatic Islets of a Genetically Susceptible Model of Type 1 Diabetes. Sports Med. Open 2017, 3, 15. [CrossRef] [PubMed]
324. Wickenberg, J.; Ingemansson, S.L.; Hlebowicz, J. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr. J. 2010, 9, 43. [CrossRef]
325. Chous, A.P.; Richer, S.P.; Gerson, J.D.; Kowluru, R.A. The Diabetes Visual Function Supplement Study (DiVFuSS). Br. J. Ophthalmol. 2016, 100, 227–234. [CrossRef]
326. Hodaei, H.; Adibian, M.; Nikpayam, O.; Hedayati, M.; Sohrab, G. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: A randomized, double-blind clinical trial. Diabetol. Metab. Syndr. 2019, 11, 41. [CrossRef]
327. Zhang, Y.; Li, X.; Zou, D.; Liu, W.; Yang, J.; Zhu, N.; Huo, L.; Wang, M.; Hong, J.; Wu, P.; et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 2008, 93, 2559–2565. [CrossRef]
328. Li, Z.; Geng, Y.N.; Jiang, J.D.; Kong, W.J. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid. Based Complement. Altern. Med. 2014, 2014, 289264. [CrossRef]
329. Chang, W.; Chen, L.; Hatch, G.M. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem. Cell Biol. 2015, 93, 479–486. [CrossRef]
330. Chatuphonprasert, W.; Lao-Ong, T.; Jarukamjorn, K. Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide. Pharm. Biol. 2013. [CrossRef]
331. Wu, X.; Li, Y.; Wang, Q.; Li, W.; Feng, Y. Effects of berberine and pomegranate seed oil on plasma phospholipid metabolites associated with risks of type 2 diabetes mellitus by U-HPLC/Q-TOF-MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2015, 1007, 110–120. [CrossRef]
332. Pang, B.; Zhao, L.H.; Zhou, Q.; Zhao, T.Y.; Wang, H.; Gu, C.J.; Tong, X.L. Application of berberine on treating type 2 diabetes mellitus. Int. J. Endocrinol. 2015, 2015, 905749. [CrossRef] [PubMed]
333. Zhang, Q.; Li, Y.; Chen, L. Effect of berberine in treating type 2 diabetes mellitus and complications and its relevant mechanisms. Zhongguo Zhong Yao Za Zhi 2015, 40, 1660–1665. [PubMed]
334. Yin, J.; Xing, H.; Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008, 57, 712–717. [CrossRef] [PubMed]
335. Zhang, H.; Wei, J.; Xue, R.; Wu, J.D.; Zhao, W.; Wang, Z.Z.; Wang, S.K.; Zhou, Z.X.; Song, D.Q.; Wang, Y.M.; et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010, 59, 285–292. [CrossRef]
336. Gu, Y.; Zhang, Y.; Shi, X.; Li, X.; Hong, J.; Chen, J.; Gu, W.; Lu, X.; Xu, G.; Ning, G. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010, 81, 766–772. [CrossRef]
337. Deng, X.W.; Xie, N. Progress of berberine for treatment of type 2 diabetes. Zhongguo Zhong Yao Za Zhi 2014, 39, 1374–1378.
338. Bahadoran, Z.; Mirmiran, P.; Hosseinpanah, F.; Hedayati, M.; Hosseinpour-Niazi, S.; Azizi, F. Broccoli sprouts reduce oxidative stress in type 2 diabetes: A randomized double-blind clinical trial. Eur. J. Clin. Nutr. 2011, 65, 972–977. [CrossRef]
339. Bahadoran, Z.; Mirmiran, P.; Azizi, F. Potential efficacy of broccoli sprouts as a unique supplement for management of type 2 diabetes and its complications. J. Med. Food 2013, 16, 375–382. [CrossRef]
340. He, R.; Alashi, A.; Malomo, S.A.; Girgih, A.T.; Chao, D.; Ju, X.; Aluko, R.E. Antihypertensive and free radical scavenging properties of enzymatic rapeseed protein hydrolysates. Food Chem. 2013, 141, 153–159. [CrossRef]
341. Duran, C.G.; Burbank, A.J.; Mills, K.H.; Duckworth, H.R.; Aleman, M.M.; Kesic, M.J.; Peden, D.B.; Pan, Y.; Zhou, H.; Hernandez, M.L. A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation. Respir. Res. 2016, 17, 89. [CrossRef] [PubMed]
342. Bahadoran, Z.; Mirmiran, P.; Hosseinpanah, F.; Rajab, A.; Asghari, G.; Azizi, F. Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. Diabetes Res. Clin. Pract. 2012, 96, 348–354. [CrossRef] [PubMed]
343. Bahadoran, Z.; Tohidi, M.; Nazeri, P.; Mehran, M.; Azizi, F.; Mirmiran, P. Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: A randomized double-blind clinical trial. Int. J. Food Sci. Nutr. 2012, 63, 767–771. [CrossRef] [PubMed]
344. Ren, Z.; Xie, Z.; Cao, D.; Gong, M.; Yang, L.; Zhou, Z.; Ou, Y. C-Phycocyanin inhibits hepatic gluconeogenesis and increases glycogen synthesis via activating Akt and AMPK in insulin resistance hepatocytes. Food Funct. 2018, 9, 2829–2839. [CrossRef] [PubMed]
345. Sadek, K.M.; Lebda, M.A.; Nasr, S.M.; Shoukry, M. Spirulina platensis prevents hyperglycemia in rats by modulating gluconeogenesis and apoptosis via modification of oxidative stress and MAPK-pathways. Biomed. Pharmacother. 2017, 92, 1085–1094. [CrossRef]